Stocklytics Platform
Asset logo for symbol COLL
Collegium Pharmaceutical
COLL89
$32.43arrow_drop_up1.53%$0.49
High Quality
Asset logo for symbol COLL
COLL89

$32.43

arrow_drop_up1.53%

Income Statement (COLL)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT$49.47M$65.99M$49.55M$39.66M$24.62M
EBITDA$84.90M$101.45M$86.70M$78.01M$65.65M
gross Profit$91.45M$94.63M$80.31M$73.82M$77.40M
NET Income$27.71M$31.94M$20.63M$13.00M-$17.42M
total Revenue$144.92M$149.74M$136.70M$135.54M$144.76M

Balance Sheet (COLL)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt$401.38M$435.33M$459.85M$478.60M$536.75M
stockholders Equity$222.16M$195.43M$178.87M$200.80M$179.73M
total Assets$1.11B$1.14B$1.17B$1.21B$1.21B
total Debt$629.99M$674.28M$718.38M$762.35M$806.23M
total Liabilities$892.08M$947.87M$998.70M$1.01B$1.03B

Cash Flow (COLL)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow-$54.14M-$67.82M-$95.41M-$45.23M$68.29M
free Cash Flow$61.36M$73.17M$73.95M$99.66M$27.49M
investing Cash Flow----$41.71M-$176.00K
operating Cash Flow$61.93M$73.33M$74.01M$99.72M$27.67M

Collegium Pharmaceutical (COLL) Financials

The income statement of Collegium Pharmaceutical Inc (COLL) provides valuable insights into the financial performance of the company. It outlines the revenue generated by the company during a specific period and deducts the cost of goods sold to determine the gross profit. This figure represents the amount remaining after covering the direct expenses associated with producing and delivering the company's products or services. Assessing the gross profit can help investors gauge the efficiency of Collegium Pharmaceutical's operations and its ability to generate profits.

Another important metric derived from the income statement is earnings before interest and taxes (EBIT). EBIT measures the company's profitability before accounting for interest and tax expenses. By excluding these factors, it allows for a more direct comparison between companies and better analysis of their core operations. Collegium Pharmaceutical's EBIT figure provides a clearer picture of its operating performance and helps investors assess its ability to generate profits solely from its business activities.

EBITDA, or earnings before interest, taxes, depreciation, and amortization, is another valuable metric to consider. By including additional non-cash expenses (depreciation and amortization), EBITDA provides a broader view of Collegium Pharmaceutical's profitability. It measures the company's ability to generate cash flow from its core operations, which can be especially important in industries with high capital expenditures or significant depreciation of assets. EBITDA is often a key metric used by investors to evaluate the financial health and efficiency of a company.

The net income from stockholders is an important figure to consider when evaluating Collegium Pharmaceutical's financial performance. It represents the profit or loss attributable to the company's stockholders after deducting all expenses, including taxes and interest. Net income reflects the overall profitability of the company and indicates its ability to generate returns for its shareholders.

Collegium Pharmaceutical's total revenue is a crucial indicator of its financial performance. It encompasses all the revenue generated by the company from its various business activities, including the sales of its pharmaceutical products. Total revenue is a fundamental metric used by investors to assess the size and growth potential of a company, as well as its ability to generate cash flow and profits.

The balance sheet of Collegium Pharmaceutical provides a snapshot of the company's financial position at a specific point in time. It includes information about the company's assets, liabilities, and stockholders' equity. The balance sheet is divided into two main sections: the left-hand side lists the company's assets, while the right-hand side lists its liabilities and stockholders' equity. By examining the balance sheet, investors can determine the financial health and stability of the company, as well as its ability to cover its obligations and generate returns for its shareholders.

Cash equivalents are a vital component of Collegium Pharmaceutical's financials. They represent highly liquid assets that can be readily converted into cash within a short period, typically within three months. Cash equivalents include cash on hand, as well as short-term investments such as treasury bills and money market funds. Assessing the amount of cash equivalents can provide insights into Collegium Pharmaceutical's liquidity and financial flexibility.

Net debt is an important financial metric that reflects the company's overall indebtedness. It is calculated by subtracting any cash and cash equivalents from the total debt. Net debt provides a more accurate picture of the company's financial obligations and its ability to meet those obligations. High net debt levels can indicate higher financial risk, as the company may have difficulty repaying its debts and may face higher interest expenses.

Stockholders' equity, also referred to as shareholders' equity or book value, represents the residual interest in the assets of Collegium Pharmaceutical after deducting liabilities. It is the amount that would be left for stockholders if all assets were sold and all liabilities were paid off. Stockholders' equity is an important measure of the company's net worth and indicates the claim that shareholders have on the company's assets.

Total assets represent the sum of all the resources owned or controlled by Collegium Pharmaceutical. This includes both current assets, such as cash and inventory, as well as non-current assets, such as property, plant, and equipment. Assessing the total assets allows investors to understand the size and value of the company's asset base and its ability to generate future cash flows.

Total debt is an important financial metric that reflects the company's total obligations to creditors. It includes both short-term and long-term debt, such as loans, bonds, and other borrowing arrangements. Total debt provides insights into Collegium Pharmaceutical's overall leverage and its ability to meet its financial obligations. High levels of total debt can indicate higher financial risk and may impact the company's ability to access additional financing or invest in future growth opportunities.

Total liabilities represent the company's overall financial obligations or debts. It includes both current liabilities, such as accounts payable and short-term debt, as well as long-term liabilities, such as bonds and long-term debt. Assessing the total liabilities helps investors evaluate the financial risk and stability of Collegium Pharmaceutical. High levels of liabilities can indicate that the company may face challenges in meeting its obligations or may have limited financial flexibility.

Cash flow is a vital aspect of Collegium Pharmaceutical's financial performance. It represents the movement of cash into and out of the company over a specific period. Cash flow can be further divided into three categories: operating cash flow, investing cash flow, and financing cash flow. By analyzing the cash flow statement, investors can assess how effectively Collegium Pharmaceutical generates and manages cash and evaluate its ability to fund future operations and growth initiatives.

Financing cash flow is a component of Collegium Pharmaceutical's overall cash flow and represents the cash flow generated from or used to finance the company's financing activities. This includes cash flows from issuing or repurchasing stock, dividend payments, and debt financing activities. Analyzing the financing cash flow can provide insights into how Collegium Pharmaceutical funds its operations and growth initiatives and how it manages its capital structure.

Free cash flow is a crucial metric used by investors to evaluate Collegium Pharmaceutical's financial performance. It represents the cash generated by the company after deducting capital expenditures necessary to maintain or expand its asset base. Free cash flow is an important indicator of the company's ability to generate cash from its ongoing operations and is often used to assess its ability to pay dividends, reduce debt, or invest in growth opportunities. Positive free cash flow indicates that Collegium Pharmaceutical has surplus cash available after meeting its essential capital needs.

Investing cash flow is a component of Collegium Pharmaceutical's overall cash flow and represents the cash flow generated from or used for the company's investing activities. This includes cash flows from the purchase or sale of long-term assets, such as property, plant, and equipment, as well as investments in other companies or securities. Analyzing the investing cash flow can provide insights into how Collegium Pharmaceutical allocates its capital and invests in its future growth and expansion.

Operating cash flow is a key metric used to assess Collegium Pharmaceutical's ability to generate cash from its core operations. It represents the cash flow generated by the company's day-to-day business activities, such as the sale of its products or provision of services, after deducting operating expenses and taxes. Positive operating cash flow indicates that Collegium Pharmaceutical is able to generate sufficient cash to cover its ongoing expenses and invest in future growth initiatives.

add Collegium Pharmaceutical  to watchlist

Keep an eye on Collegium Pharmaceutical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level